



Canadian
Cancer Clinical
Trials Network

Réseau canadien
d'essais cliniques
sur le cancer

Canadian Cancer Clinical Trials Network

3CTN Y10Q4 Performance Report

January 1, 2024 – March 31, 2024


Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials	2
Patient Recruitment at All Network Sites	2
Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment	3
Portfolio Trials and Accruals by Region/Site	4
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Alberta, British Columbia, and Manitoba	4
Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba	5
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Ontario	6
Number of active recruiting 3CTN Portfolio trials – Ontario	7
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Newfoundland and Quebec.....	8
Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec.....	9
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Pediatric Cancer Centres.....	10
Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres	11
Section B: 3CTN Portfolio Metrics.....	12
Active Recruiting Portfolio Trials by Disease Site and Phase	12
Overview of Portfolio Applications – Process Efficiency.....	13
Trials Added to the 3CTN Portfolio in Y10Q4 (January 1 – March 31, 2024).....	14

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 100% within five years.



Notes:

- 869 patients were recruited (836 to Adult and 33 to Pediatric cancer centres) to Portfolio trials in Quarter 4 bring the Y10 Network total to 3833.
- Overall, ~24% of Adult Sites (9 out of 38) met or exceeded their Y10 target of 85% above pre-3CTN baseline.
- In the end the adult network was 527 patients away from reaching the Y10 target of 4229 patients
- *Pediatric progress to pre-3CTN baseline recruitment is shown.

Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment

Objective: To improve trial access and overcome barriers to trial participation for under-represented populations.

Network Site	Primary Site Remote Access Patient*	Satellite Site Remote Access Patient	AYA Accrual Aged (15-39)
Grand River Regional Cancer Centre	0	2	0
Windsor Regional Cancer Centre	0	1	0
Juravinski Cancer Centre	0	0	5
Walker Family Cancer Centre	1	0	0
Sunnybrook Health Sciences Centre	0	0	4
Humber River Hospital	0	0	5
Royal Victoria Regional Health Centre	0	0	1
Trillium Health Partners - Credit Valley Hospital	0	1	0
CancerCare Manitoba	0	0	2
BC Cancer – Vancouver	0	0	5
BC Cancer – Kelowna	0	0	1
Tom Baker Cancer Centre	0	0	2
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	2	0	9
Centre hospitalier universitaire de Sainte-Justine	2	1	5
Montreal Children’s Hospital	0	0	2
BC Children’s Hospital	0	0	2
Children’s Hospital of Eastern Ontario	2	0	4
Children’s Hospital - London Health Sciences Centre	3	0	1
McMaster Children's Hospital - Hamilton Health Sciences Centre	1	0	0
IWK Health Centre	3	0	1
Jim Pattison Children’s Hospital	4	0	0
Stollery Children’s Hospital	0	0	1
The Hospital for Sick Children	2	0	1
Total	20	5	56

*Table excludes remote access patients recruited through the Canadian Remote Access Framework for Clinical Trials (CRAFT) proof of concept project. Numbers based on date of remote access initiation.

Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10					
						Q1	Q2	Q3	Q4	% of Baseline	% of Target
CancerCare Manitoba	99	51	44	59	90	22	9	20	7	59%	32%
Western Manitoba Cancer Centre	1	1	0	1	4	1	0	0	0	100%	54%
Manitoba Total	100	51	44	60	94	23	9	20	7	59%	32%
BC Cancer – Vancouver	106	110	154	175	203	46	58	25	19	140%	75%
BC Cancer – Abbotsford	16	1	1	2	8	1	2	2	2	44%	24%
BC Cancer – Prince George	1	10	14	21	13	3	5	0	1	900%	486%
BC Cancer – Kelowna	38	33	36	35	56	20	20	15	11	174%	94%
BC Cancer – Victoria	26	78	40	42	35	8	20	14	31	281%	152%
BC Cancer – Surrey	44	0	0	0	21	14	6	2	5	61%	33%
British Columbia Total	231	232	245	275	336	92	111	58	69	143%	77%
Cross Cancer Institute	102	310	202	118	0	19	14	25	7	64%	34%
Tom Baker Cancer Centre	76	341	248	166	0	16	15	16	14	80%	43%
Alberta Total	178	651	450	284	0	35	29	41	21	71%	38%
Western Region Total	509	934	739	619	430	150	149	119	97	101%	55%

Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2023-24)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
CancerCare Manitoba	37	13	20	18	17	17	17	15	15	17	17	16	17	19	14	15	14
Western Manitoba Cancer Centre	0	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2
BC Cancer – Vancouver	50	16	17	19	28	29	27	29	30	31	40	40	43	44	44	46	35
BC Cancer – Abbotsford	6	1	1	0	0	0	1	1	2	2	3	2	2	2	2	3	4
BC Cancer – Prince George	2	4	5	4	6	6	5	5	8	3	4	5	5	5	5	6	10
BC Cancer – Kelowna	23	4	5	5	5	8	8	8	4	10	10	10	11	11	11	16	17
BC Cancer – Victoria	12	7	9	7	10	11	8	9	10	11	9	9	9	13	13	15	18
BC Cancer – Surrey	6	-	-	-	-	-	-	-	-	7	7	7	7	7	6	6	8
Cross Cancer Institute	29	14	25	22	22	25	22	22	22	-	-	-	-	19	19	32	21
Tom Baker Cancer Centre	20	28	28	23	25	23	25	25	22	-	-	-	-	29	27	23	32

Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Ontario

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10					
						Q1	Q2	Q3	Q4	% of Baseline	% of Target
London Health Sciences Centre	186	942	693	656	506	260	123	159	153	374%	202%
Grand River Regional Cancer Centre	20	19	24	23	58	8	12	8	4	160%	86%
Windsor Regional Cancer Centre	14	3	2	3	2	1	4	3	3	79%	42%
Juravinski Cancer Centre	181	217	142	190	136	42	41	54	33	94%	51%
Cambridge Memorial Hospital	11	8	9	11	6	0	0	0	0	0%	0%
St. Joseph's Healthcare Hamilton	21	20	54	87	56	12	4	7	0	110%	59%
Walker Family Cancer Centre	17	40	7	23	38	5	3	5	0	76%	41%
Oakville Trafalgar Memorial Hospital	1	-	-	-	0	0	0	0	0	0%	0%
Sunnybrook Health Sciences Centre	141	638	395	671	593	143	171	191	203	502%	271%
Humber River Health	1	3	4	2	14	11	7	9	5	3200%	1730%
Michael Garron Hospital	2	0	0	0	0	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	543	267	338	390	158	107	139	84	123%	67%
Markham Stouffville Hospital	1	6	3	0	6	0	0	1	0	100%	54%
Mount Sinai Hospital	21	7	67	543	121	1	1	0	0	10%	5%
Northeast Cancer Centre	24	17	7	2	5	2	3	1	2	33%	18%
North York General Hospital	1	7	7	10	21	2	0	3	0	500%	270%
Royal Victoria Regional Health Centre	8	25	13	44	37	7	8	7	5	338%	182%
St. Michael's Hospital	19	3	0	9	1	9	2	1	5	89%	48%
Southlake Regional Health Centre	10	32	9	13	9	0	1	1	11	130%	70%
Thunder Bay Regional Health Sciences Centre	26	4	2	39	22	0	1	4	14	73%	40%
Trillium Health Partners - Credit Valley Hospital	27	10	2	10	12	0	1	10	12	85%	46%
William Osler Health System	1	16	2	3	6	0	1	0	3	400%	216%
The Ottawa Hospital Cancer Centre	132	804	483	771	830	190	108	155	117	432%	233%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	89	59	52	48	11	11	5	10	90%	49%
R.S. McLaughlin Durham Regional Cancer Centre	22	36	3	7	26	4	2	4	6	73%	39%
Central Region Total	1324	3489	2254	3507	2943	866	611	767	670	220%	119%

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
London Health Sciences Centre	79	45	47	44	41	42	38	39	36	32	29	31	29	30	27	29	46
Grand River Regional Cancer Centre	11	8	8	8	8	6	7	7	8	11	11	11	11	10	10	10	12
Windsor Regional Cancer Centre	4	4	2	2	2	2	2	2	2	8	3	3	3	3	3	4	8
Juravinski Cancer Centre	51	13	31	34	35	38	31	35	37	36	29	27	27	36	25	21	27
Cambridge Memorial Hospital	5	2	2	2	2	2	3	3	2	2	2	2	2	2	0	0	0
St. Joseph's Healthcare Hamilton	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	3
Walker Family Cancer Centre	10	8	7	7	7	6	6	6	8	8	8	8	7	7	7	7	5
Oakville Trafalgar Memorial Hospital		-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0
Sunnybrook Health Sciences Centre	10	47	35	34	33	32	30	35	40	45	48	48	53	50	48	49	41
Humber River Health	0	3	2	1	1	1	0	2	1	0	1	1	1	1	1	1	3
Michael Garron Hospital	3	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0
Princess Margaret Cancer Centre	91	80	81	82	65	68	68	66	64	73	74	74	75	81	78	81	58
Markham Stouffville Hospital	0	1	1	1	1	0	0	1	1	2	2	2	2	1	1	2	3
Mount Sinai Hospital	6	3	2	2	3	3	2	3	3	3	3	3	4	4	4	4	2
Northeast Cancer Centre	10	8	7	7	8	9	9	9	9	9	9	9	11	10	10	9	6
North York General Hospital	0	2	3	4	4	4	5	5	5	5	5	5	3	3	1	1	2
Royal Victoria Regional Health Centre	5	10	9	10	10	12	13	11	11	12	12	12	12	12	11	12	9
St. Michael's Hospital	4	2	2	1	1	1	1	2	1	1	1	1	1	2	2	2	7
Southlake Regional Health Centre	3	6	6	6	6	8	7	9	9	9	9	9	9	9	8	8	3
Thunder Bay Regional Health Sciences Centre	8	0	0	3	3	2	3	4	5	4	4	5	5	4	5	6	7
Trillium Health Partners - Credit Valley Hospital	9	0	0	1	4	6	6	6	7	7	6	6	6	6	6	6	9
William Osler Health System	0	1	1	1	3	2	2	1	2	2	2	2	2	2	2	2	2
The Ottawa Hospital Cancer Centre	56	10	27	29	35	37	43	44	43	39	37	38	38	38	34	33	42
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	21	21	21	20	21	21	23	24	21	20	20	18	19	18	17	17
R.S. McLaughlin Durham Regional Cancer Centre	13	0	2	1	1	3	3	4	3	6	8	8	8	8	5	7	14

Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10					
						Q1	Q2	Q3	Q4	% of Baseline	% of Target
Eastern Regional Health Authority	15	16	5	10	17	3	0	0	8	73%	40%
Atlantic Total	15	36	5	10	17	3	0	0	8	73%	40%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	155	90	156	127	30	21	28	13	106%	57%
CHU de Québec – Université Laval, adults	180	309	372	456	198	38	55	29	48	94%	51%
Quebec Total	267	464	462	612	325	68	76	57	61	98%	53%
Eastern Region Total	282	500	467	622	342	71	76	57	69	54%	29%

Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Eastern Regional Health Authority	6	0	6	7	7	9	8	8	6	5	5	6	5	5	4	3	7
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	17	18	17	25	29	28	27	21	21	22	22	22	29	27	27	17
CHU de Québec – Université Laval, adults	39	27	30	30	23	31	34	31	30	31	30	29	28	32	30	30	28

Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10				
						Q1	Q2	Q3	Q4	% of Baseline
BC Children's Hospital	34	-	30	24	19	4	3	3	6	47%
CancerCare Manitoba - Pediatrics	18	7	12	6	9	1	2	2	5	56%
Centre hospitalier universitaire de Sainte-Justine	42	38	51	54	21	8	6	5	5	57%
Children's Hospital - London Health Sciences Centre	12	-	5	5	14	1	0	1	2	33%
Children's Hospital of Eastern Ontario	20	-	14	16	16	8	4	4	1	85%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	21	29	26	18	4	3	5	0	71%
IWK Health Centre	20	-	6	11	9	4	2	0	2	40%
Janeway Children's Health and Rehabilitation Centre	4	0	5	2	5	0	0	0	0	0%
Jim Pattison Children's Hospital	6	-	7	3	4	1	0	0	3	67%
McMaster Children's Hospital - Hamilton Health Sciences Centre	14	-	16	24	16	1	1	2	0	29%
Montreal Children's Hospital	24	10	16	20	13	0	3	0	3	25%
Stollery Children's Hospital	11	-	20	23	11	3	2	3	1	82%
The Hospital for Sick Children	91	-	26	73	43	3	7	2	5	19%
Pediatric Total	313	76	256	301	198	38	33	27	33	42%


Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC Children’s Hospital	15	13	15	15	17	17	17	17	17	18	19	19	19	20	19	20	17
CancerCare Manitoba - Pediatrics	19	9	11	11	13	14	16	16	20	20	20	21	21	22	22	24	28
Centre hospitalier universitaire de Sainte-Justine	9	17	18	19	22	22	27	29	27	29	24	22	24	29	24	26	36
Children’s Hospital - London Health Sciences Centre	5	14	14	15	18	16	16	14	18	17	16	16	16	17	16	16	14
Children’s Hospital of Eastern Ontario	8	8	11	12	17	16	14	16	16	17	17	17	22	17	14	13	19
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	15	15	15	20	21	20	22	23	19	24	23	22	24	21	22	25
IWK Health Centre	9	19	20	22	23	20	19	21	23	25	25	26	26	30	29	31	25
Janeway Children's Health and Rehabilitation Centre	5	7	8	8	10	10	13	10	9	10	10	10	10	11	13	11	11
Jim Pattison Children’s Hospital	7	8	8	8	8	8	7	7	8	8	8	8	8	8	8	8	10
McMaster Children's Hospital - Hamilton Health Sciences Centre	8	12	13	14	17	17	20	20	24	25	25	25	25	25	25	25	14
Montreal Children’s Hospital	5	16	17	15	22	22	24	25	26	27	30	30	27	28	27	24	33
Stollery Children’s Hospital	3	9	11	13	13	14	13	12	13	15	15	15	16	17	16	16	20
The Hospital for Sick Children	13	16	17	17	23	24	30	27	28	28	27	27	27	29	31	30	34

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time.

Portfolio Approval Process Timeline¹

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2017	45	47	22	6
2018	46	44	18	5
2019	45	45	42	3
2020	41	41	27	0
2021	59	63	29	1
2022	36	33	3	0
2023	41	42	12	0
2024	23	22	3	0

Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed ²	Average FPR Time (days) ³	Median FPR Time (days) ³
2017	4	5	79	74
2018	10	7	84	77
2019	16	17	112	86
2020	7	6	137	134
2021	9	13	112	108
2022	3	1	44	44
2023	6	7	63	58
2024	2	2	26	26

¹ From Portfolio application receipt date to date of approval decision for period beginning Jan 13, 2015.

² Counts are based on the completed reviews in that calendar year. E.g., for an application submitted for review in 2019 but completed in 2020, the FPR will be counted for 2020.

³ FPR process begins on the date the applicant agrees to initiate the FPR process and ends on the date when the final reviewer package is submitted to 3CTN (data based on completed FPRs).

Link: [Portfolio Applications Report](#)

Trials Added to the 3CTN Portfolio in Y10Q4 (January 1 – March 31, 2024)

Trial short title	Trial phase	Disease site	Complexity rating	Trial link
(UHN) 21-5539 / CaRE-AC	Phase II	Breast or Colorectal	Low	NCT05424068
(NRG) NRG-GU009 / PREDICT-RT	Phase III	Genito-Urinary	Standard	NCT04513717
(UHN) 21-5188 / NurseNed	Not Applicable	Genito-Urinary	Low	NCT05033301
(ARCAGY/ GINECO) GINECO-EN105b / DOMENICA	Phase III	Gynecological	High	NCT05201547
(COG) ANHL2121	Phase II	Hematology	High	NCT05828069
(EMN) EMN28 / 68284528MMY3005 / CARTITUDE-6	Phase III	Hematology	Standard	NCT05257083
(LHRI) RESPIRE ILD	Phase II	Lung	Standard	NCT05986318
(UHN) 22-5650 / SuPERIOR	Phase II	Lung	Standard	NCT06191250
(ANZCHOG) OPTIMISE	Phase I/II	Solid Tumor	High	NCT06208657

Link: [3CTN's Portfolio Trial Listing](#)